LDLRAP1 Genotype

If you or a relative has stubbornly high cholesterol that runs in the family, the cause is usually one of the well-known genes that doctors check first. But a rare second pathway exists, and it can be missed entirely unless you specifically look for it. LDLRAP1 (low-density lipoprotein receptor adaptor protein 1) is one of those overlooked genes.

This test reads the DNA sequence of LDLRAP1 to see whether you carry variants that disrupt how your liver clears LDL cholesterol. The result is a once-in-a-lifetime answer about a specific inherited risk that standard cholesterol panels and even most familial hypercholesterolemia (FH) workups can overlook.

What LDLRAP1 Actually Does

LDLRAP1 makes a small helper protein that grabs onto the inside tail of the LDL receptor, the docking station on your liver cells that pulls LDL particles out of the blood. Without this helper, the docking station cannot pull the LDL inside the cell efficiently. The cholesterol stays in your bloodstream instead of being cleared.

When both copies of the LDLRAP1 gene carry damaging variants, the result is a condition called autosomal recessive hypercholesterolemia (ARH). LDL cholesterol climbs to very high levels and behaves much like the most severe inherited form of high cholesterol. In a pediatric cohort of seven children with two damaged LDLRAP1 copies, untreated LDL averaged around 507 mg/dL.

How It Differs From Standard Familial Hypercholesterolemia

Most inherited high cholesterol comes from variants in LDLR, APOB, or PCSK9, and those follow a dominant pattern: one bad copy is enough to raise LDL. LDLRAP1 is different. It usually takes two damaged copies to push cholesterol into the danger zone. Across multiple genetic studies, LDLRAP1 variants explain less than 1 percent of molecularly diagnosed FH cases worldwide.

That rarity is exactly why a targeted test matters for the right person. Patients have been labeled as having dominant FH for years, only to discover through panel-based genetic testing that they actually carry two LDLRAP1 variants. The diagnosis changes everything about family screening: in dominant FH, half of first-degree relatives are expected carriers, while in ARH, single-copy carriers in the family usually have normal or only mildly elevated cholesterol.

Heart Disease Risk

People with two damaged LDLRAP1 copies carry LDL levels that drive early atherosclerosis. In a Spanish series of seven patients with ARH, LDL remained above 185 mg/dL even on treatment. In Italian data, ARH patients still developed premature atherosclerosis despite aggressive therapy, though their long-term outcomes were generally less severe than those of homozygous LDLR-driven FH.

Single-copy carriers are a more nuanced story. Most heterozygous LDLRAP1 carriers have normal LDL levels. But a Finnish study tracking a rare missense variant (Arg151Trp) across 688 carriers found those carriers used more cholesterol-lowering medication and underwent more coronary procedures than non-carriers, suggesting some specific single-copy variants still nudge risk upward.

When LDLRAP1 Combines With Other Cholesterol Genes

The picture gets more severe when an LDLRAP1 variant sits alongside a variant in another cholesterol gene. Reports of people carrying both an LDLR variant and an LDLRAP1 variant describe unusually large cholesterol deposits in tendons (xanthomas) and accelerated atherosclerosis, even when LDL levels look similar to single-LDLR-variant cases. This is one of the practical reasons multi-gene panels matter: the combinations can be more dangerous than any single variant alone.

Why Standard Labs Can Look Reassuring And Still Miss This

A normal lipid panel in your relatives does not rule out LDLRAP1-driven disease in you. Because the condition usually requires two damaged copies, your parents may each carry one silent variant with normal cholesterol, and the family history can look unremarkable. Consanguinity (when parents are biologically related) raises the odds of two damaged copies meeting in a child, but ARH has been reported in non-consanguineous families too. The only way to know is to look at the DNA itself.

What This Test Detects That Others Miss

What this means for you: if your LDL is severely elevated, a family member was diagnosed with ARH, or your parents are biologically related and you have stubborn high cholesterol, LDLRAP1 testing answers a question the other tools cannot.

One-Time Result, Lifelong Action

Your LDLRAP1 sequence does not change. You do not need to repeat this test. The value comes from translating the result into ongoing decisions: how aggressively to monitor your LDL, when to start cholesterol-lowering therapy, and whether your siblings, children, or parents should be tested.

If you are a carrier of a clearly damaging variant, your companion lipid testing should become more frequent. A baseline lipid panel now, retesting within 3 to 6 months if you start or change therapy, and at least annual lipid panels afterward is a reasonable cadence. The genetic result is the anchor; the lipid panels are the moving instrument.

When Results Can Be Misleading

• Variant panel coverage: the test only detects the specific LDLRAP1 variants it is designed to read. A negative result does not rule out every rare variant in the gene, especially novel ones that appear in only one family.
• Variants of uncertain significance: an unexpected change in LDLRAP1 may be reported with unclear meaning. This is not a yes-or-no diagnosis, it is an open question that may need expert review or family-member testing to resolve.
• Single-copy interpretation: carrying just one damaged copy is usually not enough to cause ARH, and most carriers have normal cholesterol. Treating a single-copy result like a confirmed diagnosis can lead to unnecessary anxiety or over-treatment.
• Ancestry-specific variants: some LDLRAP1 variants are concentrated in particular populations (such as the Arg151Trp variant in Finnish people, or specific variants in Sardinian, Lebanese, and Middle Eastern families). A standard panel may not include every population-relevant variant.

What To Do With An Out-of-Pattern Result

If you carry two damaging LDLRAP1 variants, the next steps are straightforward: confirm the result with a different method if there is any uncertainty about the variant call, get a full lipid panel including ApoB and Lp(a), and start a conversation with a lipidologist about aggressive LDL lowering. Pediatric and adult ARH patients in published cohorts have responded well to combinations of statins, ezetimibe, and, when needed, newer agents.

If you carry one damaging variant, your management is usually driven by your own lipid numbers rather than by the genotype alone. Most single-copy carriers do not need ARH-specific treatment, but knowing the result helps your children and siblings make informed decisions about their own testing.

In either case, a genetic counselor can help you decide which family members to test, in what order, and how to interpret what comes back. For families with biallelic variants, cascade testing of first-degree relatives is the most efficient way to find other affected people early, before atherosclerosis takes hold.